Morgan Stanley Maintains Invivyd(IVVD.US) With Buy Rating, Maintains Target Price $3.55
Invivyd Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Invivyd, Lowers Price Target to $10
Morgan Stanley Maintains Invivyd(IVVD.US) With Buy Rating, Cuts Target Price to $3.55
Invivyd's Resilient Strategy and Prospective Growth: Buy Rating Affirmed Amidst Pemgarda Setbacks and New Antibody Developments
Invivyd Analyst Ratings
Invivyd Initiated at Buy by EF Hutton
EF Hutton Initiates Coverage On Invivyd With Buy Rating, Announces Price Target of $9
Morgan Stanley Maintains Invivyd(IVVD.US) With Buy Rating, Maintains Target Price $9.5
Invivyd Analyst Ratings
Morgan Stanley Maintains Invivyd(IVVD.US) With Buy Rating, Maintains Target Price $9.5
Buy Rating Affirmed for Invivyd: Strong Product Performance and Strategic Market Initiatives
Buy Rating on Invivyd Backed by Strong Phase 3 Data and Market Catalysts
Morgan Stanley Maintains Invivyd(IVVD.US) With Buy Rating, Maintains Target Price $9.5
Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals Ltd. (OtherTLPPF) and Invivyd (IVVD)
HC Wainwright & Co. Reiterates Buy on Invivyd, Maintains $15 Price Target
Invivyd Analyst Ratings
Morgan Stanley Maintains Invivyd(IVVD.US) With Buy Rating, Cuts Target Price to $9.5
Invivyd Analyst Ratings
Invivyd Analyst Ratings
No Data